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Unlike the initial balloon ablation catheters which were designed to deliver ablation
lesions within the pulmonary veins (PVs), the current balloon catheters are fashioned
to deliver lesions out of the PV ostia. Using the current generation of balloon ablation
catheters, electrical isolation occurs at the level of the PV ostia, but the antral regions are
largely unablated because of its initial technical feasibility and presumed safety benefits,
balloon cryoablation was being increasingly employed for pulmonary vein (PV) isolation.
Other balloon technology—endoscopically navigated laser balloon—was introduced as first
real catheter ‘‘one fits all’’ with adjustable size of balloon infation.
While high percentage of acute isolation has been demonstrated in most patients with
both balloon catheters, little data are available on the chronic durability of cryoballoon or
laser balloon lesions. Our own data show that cryoballoon ablation and laser balloon
ablation allow for durable PV isolation with the use of a single balloon. With maintained
chronic isolation in most PVs, it may represent a significant step toward consistent and
lasting ablation procedures.
& 2012 Published by Elsevier Urban & Partner Sp.z o.o. on behalf of The Czech Society of
Cardiology.
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Currently, electrical pulmonary vein (PV) isolation is the
cornerstone of the catheter ablation treatment for paroxys-
mal atrial fibrillation (PAF) [1–8]. Many electrophysiologists
also believed that most of the AF triggers come from multipleed by Elsevier Urban & P
.
euzˇil).PV sites, which need to be ablated to stop AF recurrences.
Subsequent research has suggested that all PVs were also
capable of perpetuating AF. This led to the notion that
all 4 PVs needed to be ablated to maximize the efficacy of
radiofrequency (RF) ablation. Haissaguerre et al. described
mapping of the PV potentials using a specially designedartner Sp.z o.o. on behalf of The Czech Society of Cardiology..
Fig. 1 – Cartoon of left superior pulmonary vein occlusion
with Arctic Front balloon, stabilised electrically active
wire (Achieve) registered electrical potentials from each
treated vein.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 4 0 1 – e 4 0 7e402circular catheter that could be positioned at the PV ostia,
enabling one to evaluate electrical connection between PV
muscle sleeves and the left atrial muscle, making isolation of
the electrical impulse between the PV and left atrium (LA)
easily and reproducibly ascertained [3,4]. The PV isolation
(PVI) technique gave electrophysiologists a new tool to treat
AF with a catheter-based approach and instantly became
almost synonymous with AF ablation. Given the number of
all patients with AF, it is clear that we need to simplify the
procedure with respect to the acute effect and, most impor-
tantly, durability of electrical isolation. That’s why the prin-
ciple of ‘‘single shot’’ therapy needs to be extended by long-
lasting efficacy of the initial procedure. Perhaps also long-
lasting forms of AF such as persistent AF should be consid-
ered as a target for the balloon technology.
Unlike the initial balloon ablation catheters, which were
designed to deliver ablation lesions within the PVs, the
current balloon prototypes are fashioned to deliver lesions
not at the PV ostia, but extraostially. However, the actual
location of the ablation lesions using these devices is not
known.
All the aspects of the use of balloon catheters need to be taken
account of including: procedure efficacy, procedure and fluoro
exposure time, collateral damage, and other related complica-
tions. In this paper, we describe in detail cryoballoon and laser-
balloon technologies, as development of the high-intensity
focused ultrasound (HIFU) balloon (Prorhythm Inc., Ronkon-
koma, NY, USA) was stopped after several serious complications,
the duty-cycled system (Ablation Frontiers Medtronic, Carlsbad,
California, USA) has been associated with significant numbers of
silent strokes, and the Mesh ablator catheter (Bard Inc., Lowell,
MA, USA) is now in the process of redesigning.
Because of the technical difficulties associated with point-
to-point ablation using a standard spot ablation catheter with
the LA, there has been a significant effort in developing
alternative ablation catheter designs to quickly and easily
isolate PVs. The first such device tested clinically was an
ultrasound balloon ablation catheter that delivered energy
in a radial fashion at the level of the diameter of the
balloon—hence necessitating that the balloon catheter be
placed within the PV when delivering energy [9]. This balloon
design was suboptimal since the level of electrical isolation
typically excluded the proximal portions of the vein, so PV
triggers of AF located at this region would not be included
in the ablation lesion [10]. From a safety perspective, the
intra-venous location of the energy delivery resulted in PV
stenosis.
The initially the very promising HIFU balloon [9], which was
designed as the only one contactless catheter, was withdrawn
from the market as, due to uncontrolled energy delivery, it had
resulted in life-threatening complications, i.e., atrial-esophageal
fistulas.
Since this first-generation device, balloon ablation cathe-
ters have evolved considerably [11]. There are now two major
balloon-based ablation devices used in clinical practice but
still at various stages of clinical evaluation for: (i) cryoballoon
ablation, and (ii) endoscopic laser-balloon ablation. Each
of these has been fashioned to be placed at the PV ostia, so
as to theoretically isolate the veins outside their tubular
portion.2. Cryoballoon technology
To date, the largest global experience with such technology
involves the Arctic FrontTM cryoballoon (Medtronic Cryocath
LP, Pointe-Claire, Quebec, Canada)—a balloon catheter
designed for inflation at the PV ostium, thereby allowing for
temporary occlusion of PV blood flow and circumferential
ostial contact [12]. Balloon-based ablation systems potentially
offer a simpler and faster means of achieving PVI that,
theoretically, is less reliant on operator skills. At the same
time, cryothermal energy offers advantages over RF energy
including increased catheter stability, less endothelial dis-
ruption with lower thromboembolic risk, and minimal tissue
contraction with healing, an observation thought to result
in less esophageal damage and PV stenosis. With optimal
positioning, it has been demonstrated that electrical isolation
can be obtained acutely with the delivery of a single, 240-
second lesion. The system consists of a deflectable catheter
with a balloon-within-a-balloon design (two layers because of
safety reasons), wherein a cryo-refrigerant (N2O) is delivered
into the inner balloon. There are currently two sizes of the
cryoballoon, 23 and 28 mm, but there is expanding literature
evidence the bigger size (28 mm) is much more effective [13].
While deflated, the balloon catheter is deployed through a
12-French deflectable sheath. The placement into the PV is
supported by the wire inserted into the lumen of the catheter
to stabilize the balloon while being inflated in the PV. Once in
the LA and individual PV, the balloon is inflated and posi-
tioned at the PV ostium to temporarily occlude blood flow
from the targeted PV (Figs. 1, 2). After placement and occlu-
sion have been verified with the distal injection of contrast on
fluoroscopy, cryothermal energy delivery is initiated, and all
tissue in contact with the balloon is ablated. When adequate
tissue apposition cannot be achieved, as indicated by a leak
observed on intracardiac echo (ICE; AcuNav, Siemens-Ultra-
sound, Inc., Mountain View, CA, USA) or contrast fluoroscopy,
a ‘‘pull-down’’ technique can be employed. Users in many
centers now employ only the single-transseptal technique
Fig. 2 – Identical Arctic Front balloon—on fluoro in the
position of left superior pulmonary vein occlusion with
circular Achieve wire. In both examples deflectable steat
(ID 12 Fr) is used.
Fig. 3 – On cross section shown the freezing process using
the original Arctic Front balloon—23 and 28 mm size (A);
bottom (B) is the same cross section freezing process
using newer balloon Arctic Front Advance with more
homogenous cryotherapy application.
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of cryoballoon use for catheter ablation still varies among the
centers, most of the users apply 300-second lesions plus one
‘‘bonus’’ lesion. Each PV must be treated individually, in the
right superior PV, cryoenergy must be delivered together with
phrenic nerve stimulation to avoid phrenic nerve palsy,
which is the most important complication (which is impor-
tant for all balloon technologies). Besides, there is evidence
of collateral damage, specifically two reports of atrio-
esophageal fistula formation, so esophageal temperature
during the ablation should be also considered [14]. There
are two main developments of the cryoballoon system avail-
able: (i) the Arctic Front Achieve, and (ii) the Arctic Front
Advance. The first one is designed as a stiff wire with a
circular shape available to record the potentials from the
each targeted PV even during freezing. The second one is a
new balloon freezing system design with a much homoge-
neous freezing effect covering a larger surface of the balloon
(Fig. 3). The Arctic Front Advance features EvenCool Cryo
Technology providing improved cooling uniformity. To
improve the cooling uniformity on the balloon surface, the
number of injection ports was increased from four to eight,
resulting in two refrigerant jets per quadrant; the injection
coil was moved distally from its current location near the
equator; the refrigerant spray pattern was optimized; and
the flow rate for the 28-mm balloon size was increased by
16%. These product changes have resulted in reducing the
observed variability in temperatures on the cryoballoon
surface.
Centers with extensive experience have reported a pro-
gressive decrease in procedural time, fluoroscopy time, num-
ber of cryoballoon applications, and need for additional focal
ablation with increasing operator familiarity [15,16]. Likewise,
single procedural success rates have increased progressively
with increasing familiarity with the procedure (77.5% for thelatest quartile of patients treated vs 39.5% for the earliest
quartile of patients treated).
Twenty-three studies have reported the procedural success
of cryoballoon ablation for AF. Acute procedural success was
achieved in 91.67–100% of patients (19 studies; 924 patients)
and 94.87% to 100% of targeted veins (18 studies; 3803 veins).
Overall, 98.81% of patients achieved complete PVI (95% CI
97.88–99.40%), and 98.47% of targeted veins were successfully
isolated (95% CI 98.03–98.84%). Ablation with the cryoballoon
catheter alone (i.e., excluding concomitant focal ablation)
resulted in PVI in 92.64% of targeted veins (95% CI
91.76–93.45%) and complete PVI in 77.81% of patients (95%
CI 74.99–80.45%). Studies using a prespecified exclusive cryo-
balloon ablation strategy achieved complete PVI in 98.74% of
patients (8 studies, 317 patients; 95% CI 96.80–99.66%) and
99.23% of targeted veins (6 studies, 912 targeted veins; 95% CI
98.42–99.69%). Chierchia et al. [17,18] observed acute proce-
dural reconnection in 2.8% (3/104) of veins within a 60-minute
post-ablation observation period. In all cases, reconnection
occurred in the right inferior pulmonary vein (RIPV), two in
the inferior portion, and one in the posterior portion. Another
study did not report any acute reconnection after a postabla-
tion observation period of up to 30 minutes [19]. Two studies
reported a comparison of cryoballoon ablation with conven-
tional RF for paroxysmal AF. Linhart et al. [20] compared
20 patients with paroxysmal AF who underwent their first
PV ablation with the cryoballoon and matched them to 20
patients undergoing RF ablation. Six-month freedom from
documented AF did not differ between the groups (55% with
cryoballoon vs 45% with RF), although there was a non-
significant trend toward decreased AF burden in those with
a recurrence after cryoballoon ablation.
Similarly, Kojodjojo et al. [21] reported no difference in
12-month freedom from recurrent AF between those
who underwent cryoballoon ablation for paroxysmal AF (90
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and 72%, respectively).
Cryoballoon ablation was studied in STOP-AF, one of the
most important randomized trials, involving a comparison of
cryoballoon ablation with AADs for patients with paroxysmal
AF who had previously failed at least one AAD [22]. This US
study proved the efficacy of the cryoballoon technology and,
despite some important limitations (the study contained the
learning curve of most of the centers; only the 23-mm balloon
size was available with related complications—moderate PV
stenosis and phrenic nerve palsy—14%).
After a 3-month blanking period, 69.9% (114/163) of the
cryoballoon group were free of recurrent AF at 1 year versus
7.3% (6/82) of the AAD group. At 12 months, there was a
statistically significant improvement in symptoms and every
aspect of quality of life as measured by the SF-36 question-
naire in the cryoablation group. For all metrics, symptomatic
improvement was greater in the cryoablation group com-
pared with the AAD group.
It is clear that the cryoablation is associated with minimal
rates of silent strokes, as shown by several reports. The
incidence of thromboembolic complications including peri-
procedural stroke, transient ischemic attack, or myocardial
infarction was 0.57%. Compared to conventional RF catheters,
the observed microembolic signals in middle cerebral arteries
were significantly lower with the cryoballoon and irrigated RF
catheters (390872816 vs 9357463 and 14047981 total micro-
embolic signals, respectively).
In several systematic reviews, an acute procedural success
rate greater than 98% was observed. Not unexpectedly, the
most challenging PV to isolate was the RIPV, although special
techniques (‘‘hockey-stick’’, ‘‘pull-down’’ or ‘‘large loop’’) and
focal cryoablation were helpful in achieving PVI in the
majority of cases [23]. For patients with paroxysmal AF, the
1-year freedom from recurrent AF off AAD (73% with a
3-month blacking period and 60% with no blanking period)
compares favorably with results reported in the global RF
literature. In the systematic review and meta-analysis by
Calkins et al.,24 the single procedural success rate of RF
catheter ablation off AAD therapy after a mean follow-up of
14 months was 57% (50%–64%) when a 2- to 14-week blanking
period was included in a sizeable proportion of patients. In a
prospective long-term cohort study of RF ablation, the actuar-
ial arrhythmia-free survival rate after a single procedure was
39.8%75.1% with no blanking period [24,25].
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Fig. 4 – Figure of adjustable laser balloon Light Ring with 2
Fr size endoscop and light source allowing direct
visualization a energy application control; wide of laser
beam is 301, left upper part—endoscopic view of both left
veins visualized with optimal balloon—tissue contact. Right
bottom part—endoscopic view of the right upper vein with
simultaneous circular mapping catheter placement to
adjust electrical isolation.3. The laser balloon technology
The Light RingTM laser balloon catheter (CardioFocus Inc.,
Marlborough, MA, USA) is a novel complex endoscopic abla-
tion system (EAS) using adjustable balloon to adapt various
PV sizes to get ideal contact with the tissue and also allows to
titrate the power of each individual laser therapy application.
Size of the balloon is adjustable from 9mm up to 35 mm in 9
steps, it is continuously flushed by heavy water (deuterium
D2O), a 980 nm wavelength laser beam represents a 301 arc
which could be placed by rotation circumferentially around
all the PV ostia, a 2-Fr endoscopic wire is implemented so
optimal or suboptimal contact could be controlled by theoperator [26,27]. In principle, the laser generates a very
similar tissue effect compared with the RF energy source,
with some photon reflection, scattering but there is also the
‘‘hot spot’’ as in the case of RF application and conduction
heating effect. Histological findings represent fibrous tissue
with much sharper edges compared with RF. Hence, EAS
offers a fully tailored approach to the ablation, allowing
customized lesion design and nearly individualized energy
delivery that takes into account the proximity of the PVs to
the collateral anatomical structures—mainly the esophagus
and phrenic nerve.
The catheter itself is not deflectable, but it is used with a
single-direction deflectable transseptal sheat (12 Fr ID, 16 Fr
OD). Laser energy is applied for not more than 30 seconds
with preselected power (range from 5.5 to 12 W). The laser arc
could be rotated independently to the balloon under visual
control of the operator to get continuous lesion set with
overlapping the laser beam by 10–50% (Figs. 4, 5). The
majority of laser applications are visible by whitening of the
tissue while creating transmural lesion (which could be only
suspected). To confirm the lesion overlap, a second (memory)
screen could be used. Rotating, advancing and retracting
the laser beam could facilitate continuous lesion application
in respect to the amount of energy we need to apply to
guarantee a transmural lesion. This was documented by a
study conducted by the Hamburg group and reported recently
by Adreas Metzner et al. [28]. The use of higher energy leads
to better acute and chronic success rates. The superiority of
higher energy levels regarding chronic PVI has been sug-
gested on the basis of the porcine model; however, previous
studies did not assess the impact of varying energy on the
acute success rate of PVI [29]. In several reports (including the
very first preclinical one) [29], around 85–90% of PVs were
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 4 0 1 – e 4 0 7 e405isolated on the first attempt of the lesion set. In the very first
prospective multicenter study including 200 patients, 761 PVs
out of 770 (98.8%) were acutely isolated, and 604 PVs (79.4%)
were isolated on the first attempt. For complete PVI 1.3
attempts were needed [30]. To assess durability of the PVI,
52 out of 56 patients even asymptomatic, without clinical
evidence of AF recurrence were studied by the remapping
procedure. Out of initially isolated 189 Pvs, 162 were persis-
tently isolated, which represents 86% of long-lasting electri-
cal isolation; 62% of these 52 patients had all their PVs
permanently isolated. Interestingly, when PVs had not been
isolated, there was always only a very small gap within the
original ablation line [31]. If we can document this high-level
of PVI in a larger study population, it will be the best chronic
result in catheter-based ablation of AF. In an all-updated
literature review containing 687 reported patients with EAS
used for PVI, there was an average 2% of pericardial effusion/
tamponade without any report of PV stenosis, clinical TIA/
stroke, and atrio-esophageal fistula. Phrenic nerve palsy was
observed in around 3% of the patients [32].Fig. 6 – Electroanatomical map—EAM (NavX, St. Jude Medical, US
picture shows EAM (CARTO, Biosense Webster, USA) after laser b
achieved isolation, in case of laser balloon the lines are close t
Fig. 5 – Inflated Light Ring Laser balloon (fluoroscopy) in the
position of full occlusion of right inferior pulmonary vein.Boris Schmidt and Julian Chun recently compared the mid-
term effect of PVI, in a randomized fashion, the cryoballon
and laser balloon strategy with better results using the laser
balloon (73% clinical success) compared with the cryoballoon
(original version) with a 63% long-lasting success rate [33].
They also proved much less fluoroscopy time per procedure
using laser ablation. The only limitation is that the endo-
scopic view (due to the catheter shaft) does not permit full
circumferential view and the circular linear line needs to be
finished after rotation of the catheter. There are also several
papers on the way reporting silent stroke rates.
It could be summarized that the EAS system can deliver
circumferential lesions set ‘‘anatomically’’, with no real-time
electrograms and despite the fact the operator is not able to
see any electrogram until the circle is completed by around
80–84%. Another very important parameter of EAS is the
ability to directly visualize tissue and the quality of balloon/
tissue contact which guarantee constant, real-time confirma-
tion that energy is being delivered into tissue. With optimal
contact visual control, a limited respiratory and cardiac
movement artifact can also improve the outcome of the
whole procedure while the balloon moves in concert with
the targeted PV. But what we consider the most important
parameter of this very complex balloon ablation system is its
ability to carefully ‘‘overlap’’ successive lesions under direct
visualization simply because the energy is repositioned with-
out moving the catheter.4. Conclusion
Balloon-based technologies offer the advantage of ‘‘single-shot’’
isolation of the PV, thus decreasing dependence on operator
dexterity. Compared with other balloon-based ablation technol-
ogies (high-intensity focused ultrasound and the endoscopic
laser), the cryoballoon is less direction-dependent as the refrig-
erant jet inside the balloon is directed to produce the lowest
ablation temperatures in a large circular zone on the anterior
third of the balloon. As such, cryoballoon ablation may be
expected to isolate the muscular PV sleeves as well as the PV
antrum (Fig. 6). In this systematic review, we observed an acute
procedural success rate greater than 98%. This systematic review
of the cryoballoon and EAS ablation procedure for paroxysmal
AF results in high acute and medium-term efficacy rates. WeA) of the left atrium before and after cryoablation. The third
alloon ablation. All maps after application show the level of
o the LA antrum.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 4 0 1 – e 4 0 7e406have no data supporting the success rates when the cryoballoon
and EAS are used as stand-alone therapy for persistent AF.
The rate of ‘‘balloon-technology’’ procedure complications is
relatively low and includes the most prominent incidence of
phrenic nerve palsy (3–6%), most of which is transient. Further
studies, including direct comparison with conventional RF abla-
tion, are ongoing and will provide important insight into balloon
technology long-term efficacy and safety.r e f e r e n c e s
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